DEA Approves New Report in Marijuana Rescheduling Hearing as Reform Debate Intensifies

The Drug Enforcement Administration has agreed to include a federal watchdog report in the marijuana rescheduling hearing that identifies significant gaps in the government's process for evaluating controlled substances. This development comes as opponents of the Trump administration's rescheduling proposal seek additional testimony and document discovery to strengthen their case. The watchdog findings highlight systemic deficiencies in how federal agencies assess the safety and medical potential of cannabis and other controlled drugs. The inclusion of this critical report could influence the rescheduling decision and inform future regulatory frameworks for medical marijuana evaluation and approval.